NASDAQ:DRMA Dermata Therapeutics Q2 2026 Earnings Results & Report $0.57 -0.03 (-4.75%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$0.58 +0.01 (+1.56%) As of 11/17/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dermata Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.74 versus the -$0.55 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeAfter Market ClosesConference Call4:00 PM ET Dermata Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$0.55Beat/MissMissed by -$0.19One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersDermata Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsDermata Therapeutics' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dermata Therapeutics Q2 2026 Earnings FAQ Did Dermata Therapeutics beat earnings estimates for Q2 2026? Dermata Therapeutics (NASDAQ:DRMA) reported earnings of -$0.74 per share for Q2 2026, missing the consensus estimate of -$0.55. The report was announced on Tuesday, August 11, 2026. When is Dermata Therapeutics' next earnings date? Dermata Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dermata Therapeutics on the company's earnings history page. Dermata Therapeutics Earnings HeadlinesDermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational TreatmentNovember 17 at 1:23 PM | finance.yahoo.comDermata Therapeutics Highlights Tome Study Results, Surpasses 1,000 OrdersNovember 17 at 9:11 AM | tipranks.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years. | Profits Run (Ad)Dermata Therapeutics (DRMA) Set to Announce Quarterly Earnings on WednesdayNovember 17 at 1:44 AM | americanbankingnews.comDermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026November 10, 2026 | finance.yahoo.comDermata Therapeutics: Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical TrialOctober 29, 2026 | finanznachrichten.deSee More Dermata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email. Email Address About Dermata TherapeuticsDermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions. The San Diego-based company uses a proprietary technology derived from freshwater sponges to develop topical therapies. Its lead candidate, DMT310, is an investigational topical treatment being developed for acne. Dermata has also developed DMT410, a candidate that combines its sponge-based technology with botulinum toxin for potential use in dermatologic conditions. These candidates are investigational and have not been approved for marketing.View Dermata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.